Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide with Temozolomide and Radiation for Newly Diagnosed Glioblastoma
NCT00085254Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2005
- Primary completion
- Nov 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cilengitide in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Started Apr 2005; status: completed.
02
Drugs
cilengitide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00085254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085254.